CSO Forum: The Promise of Immunotherapy

Immunotherapies are saving lives. Still, they are only effective for 25% of cancer patients. Dana-Farber is dedicated to changing that statistic, leading novel approaches to harness the body’s immune system to destroy cancer cells.

Watch as Dana-Farber’s Chief Scientific Officer, Kevin Haigis, PhD, leads a discussion with three immunology experts, Judith Agudo, PhD, Stephanie Dougan, PhD, and Evanna Mills, PhD, discussing how they are using basic science to tackle some of immunology’s most complex challenges, particularly in breast cancer, colon cancer, melanoma, and pancreatic cancer. The panelists also highlight the importance of collaboration, mentorship, and empowering women scientists in continuing to move this work forward.

Give Now

Thank you for your interest in learning more about The Dana-Farber Campaign. You have been added to our email list and will receive updates on ways to join us in defying cancer. You can unsubscribe at any time.

There has been an issue submitting your request. Please try again.

Founded in Boston in 1947, Dana-Farber is a principal teaching affiliate of Harvard Medical School and a federally designated Comprehensive Cancer Center that develops and disseminates innovative patient therapies and scientific discoveries throughout the world. About Our Patient Stories: Dana-Farber shares patient stories which may include descriptions of actual medical results. Dana-Farber provides personalized care for each patient based on their unique needs; their experiences and results will vary.

At Dana-Farber we are committed to an inclusive community where human differences are valued and celebrated, and where all are welcome. We work every day to create an innovative, caring, and inclusive environment where each patient, family, and staff member feels valued and respected.